PE 22-28 vs Selank
A side-by-side research comparison of PE 22-28 and Selank across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | PE 22-28 | Selank |
|---|---|---|
| Full name | PE 22-28 (Spadin-Derived TREK-1 Peptide) | Selank (TP-7) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research peptide (preclinical) | Research compound |
| Mechanism | Selectively blocks the TREK-1 background potassium channel. TREK-1 inhibition enhances serotonergic signaling and rapidly increases synaptogenesis and neurogenesis, producing antidepressant-like effects faster than SSRIs in animal models. | Modulates GABA-A allosteric sites, increases BDNF, stabilizes enkephalin degradation, and influences serotonin metabolism. Enhances IL-6 and Th1/Th2 balance. |
| Molecular weight | ~ (7-residue peptide) | 751.9 Da |
| Half-life | Short (peptide; improved vs spadin) | 3-5 min (IV) / 15-30 min (intranasal) |
| Bioavailability | Intranasal or injection (research) | Moderate (intranasal) |
| Typical dose | Not established for humans | 250-750 mcg per spray dose |
| Frequency | Research only | 2-3x daily |
| Route | Intranasal or injection (research) | Intranasal spray |
PE 22-28 reported benefits
- Rapid antidepressant effects (preclinical)
- Promotes neurogenesis and synaptogenesis
- TREK-1 channel blockade
- Neuroplasticity research interest
Selank reported benefits
- Anxiolytic without sedation
- Improved memory/learning
- Cognitive flexibility
- Immune modulation
- BDNF upregulation
- No addiction
Related comparisons
Research and educational reference only. Not medical advice.